We will include healthy people not suffering from any diseases. We will exclude minors (less than 18 years old, pregnant women, those planning a pregnancy, and lactating women).
Conditions
Interventions
None listed
Sponsors
KAGOME CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Study design) We will include randomized controlled parallel trials (RCT-P), randomized controlled crossover trials (RCT-C), quasi-randomized controlled parallel trials (qRCT-P), quasi-randomized controlled crossover trials (qRCT-C), non-randomized controlled parallel trials (nonRCT-P), non-randomized controlled crossover trials (nonRCT-C), and non-randomized controlled trials.We will include scientific papers and reports which give us enough research details. (PICO) Participant: We will include healthy people not suffering from any diseases. We will exclude minors (less than 18 years old, pregnant women, those planning a pregnancy, and lactating women). Intervention: We define oral intake of Levilactobacillus brevis KB290 as an intervention (regardless of the form and amount of intake). Comparison: We define oral intake of test food not containing Levilactobacillus brevis KB290 or no intake of test food as controls. Outcome measurement: We will evaluate levels of water content in stratum corneum as primary outcome. (Language) Eligibility is not restricted by language.
Exclusion criteria
Exclusion criteria: We will exclude proceedings and unpublished studies which do not give us enough research details.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will evaluate the effect of Levilactobacillus brevis KB290 intake on levels of water content in stratum corneum. | — |
Countries
Japan
Contacts
Public ContactShohei Satomi
KAGOME CO., LTD. Diet & Well-being Research Institute
Outcome results
None listed